" class="no-js "lang="en-US"> Thomas Lindahl - Medtech Alert
Thursday, August 14, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Thomas Lindahl

Thomas Lindahl

About Thomas Lindahl

Thomas is a doctor with specialist training in radiology. He has a doctorate in oncology from Karolinska Institutet with a dissertation on breast cancer. Thomas has many years of experience in managerial positions in medical diagnostics. Thomas has been a part of Unilabs since February 2019.

Related Story

Artificial Intelligence

 Unilabs Sweden Launches Subtle Medical's AI-powered Imaging Technology to Further Bolstering Patient Care | Pharmtech Focus

Unilabs Sweden Launches Subtle Medical's AI-powered Imaging Technology to Further Bolstering Patient Care

July 7 2022

Unilabs, the leading diagnostic services provider, announced a partnership with Subtle Medical, a healthcare technology […]